365 related articles for article (PubMed ID: 20451371)
61. RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors.
Patel AS; Murphy KM; Hawkins AL; Cohen JS; Long PP; Perlman EJ; Griffin CA
Cancer Genet Cytogenet; 2007 Jul; 176(2):107-14. PubMed ID: 17656252
[TBL] [Abstract][Full Text] [Related]
62. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.
Takeuchi K; Soda M; Togashi Y; Sugawara E; Hatano S; Asaka R; Okumura S; Nakagawa K; Mano H; Ishikawa Y
Clin Cancer Res; 2011 May; 17(10):3341-8. PubMed ID: 21430068
[TBL] [Abstract][Full Text] [Related]
63. Anaplastic lymphoma kinase as a therapeutic target.
Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
[TBL] [Abstract][Full Text] [Related]
64. Timely topic: anaplastic lymphoma kinase (ALK) spreads its influence.
Cheuk W; Chan JK
Pathology; 2001 Feb; 33(1):7-12. PubMed ID: 11280613
[TBL] [Abstract][Full Text] [Related]
65. [Implications of ALK (anaplastic lymphoma kinase) in oncohematology].
Cluzeau T; Pécuchet N; Mounier N; Vignot S
Bull Cancer; 2010 Aug; 97(8):991-6. PubMed ID: 20483705
[TBL] [Abstract][Full Text] [Related]
66. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages.
Mariño-Enríquez A; Dal Cin P
Cancer Genet; 2013 Nov; 206(11):357-73. PubMed ID: 24091028
[TBL] [Abstract][Full Text] [Related]
67. Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).
Settleman J
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S36-41. PubMed ID: 19393834
[TBL] [Abstract][Full Text] [Related]
68. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor.
Coffin CM; Patel A; Perkins S; Elenitoba-Johnson KS; Perlman E; Griffin CA
Mod Pathol; 2001 Jun; 14(6):569-76. PubMed ID: 11406658
[TBL] [Abstract][Full Text] [Related]
69. TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins.
Armstrong F; Lamant L; Hieblot C; Delsol G; Touriol C
Eur J Cancer; 2007 Mar; 43(4):640-6. PubMed ID: 17276053
[TBL] [Abstract][Full Text] [Related]
70. Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.
Ardini E; Magnaghi P; Orsini P; Galvani A; Menichincheri M
Cancer Lett; 2010 Dec; 299(2):81-94. PubMed ID: 20934803
[TBL] [Abstract][Full Text] [Related]
71. Virtual screening and further development of novel ALK inhibitors.
Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
[TBL] [Abstract][Full Text] [Related]
72. Characterization of the expression of the ALK receptor tyrosine kinase in mice.
Vernersson E; Khoo NK; Henriksson ML; Roos G; Palmer RH; Hallberg B
Gene Expr Patterns; 2006 Jun; 6(5):448-61. PubMed ID: 16458083
[TBL] [Abstract][Full Text] [Related]
73. ALK-positive anaplastic large cell lymphoma with TPM3-ALK translocation.
Shin S; Kim J; Yoon SO; Kim YR; Lee KA
Leuk Res; 2012 Jul; 36(7):e143-5. PubMed ID: 22591683
[No Abstract] [Full Text] [Related]
74. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK).
Morris SW; Naeve C; Mathew P; James PL; Kirstein MN; Cui X; Witte DP
Oncogene; 1997 May; 14(18):2175-88. PubMed ID: 9174053
[TBL] [Abstract][Full Text] [Related]
75. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.
Griffin CA; Hawkins AL; Dvorak C; Henkle C; Ellingham T; Perlman EJ
Cancer Res; 1999 Jun; 59(12):2776-80. PubMed ID: 10383129
[TBL] [Abstract][Full Text] [Related]
76. Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models.
Nitta H; Zhang W; Kelly BD; Miller M; Pestic-Dragovich L; Bieniarz C; Vasicek TJ; Marafioti T; Rimsza L; Grogan TM
Methods; 2010 Dec; 52(4):352-8. PubMed ID: 20621192
[TBL] [Abstract][Full Text] [Related]
77. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
[TBL] [Abstract][Full Text] [Related]
78. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.
Heukamp LC; Thor T; Schramm A; De Preter K; Kumps C; De Wilde B; Odersky A; Peifer M; Lindner S; Spruessel A; Pattyn F; Mestdagh P; Menten B; Kuhfittig-Kulle S; Künkele A; König K; Meder L; Chatterjee S; Ullrich RT; Schulte S; Vandesompele J; Speleman F; Büttner R; Eggert A; Schulte JH
Sci Transl Med; 2012 Jul; 4(141):141ra91. PubMed ID: 22764207
[TBL] [Abstract][Full Text] [Related]
79. Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma.
Feldman AL; Vasmatzis G; Asmann YW; Davila J; Middha S; Eckloff BW; Johnson SH; Porcher JC; Ansell SM; Caride A
Genes Chromosomes Cancer; 2013 Nov; 52(11):1097-102. PubMed ID: 23999969
[TBL] [Abstract][Full Text] [Related]
80. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination.
Chiarle R; Martinengo C; Mastini C; Ambrogio C; D'Escamard V; Forni G; Inghirami G
Nat Med; 2008 Jun; 14(6):676-80. PubMed ID: 18469826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
